MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Revenue
$80,104K
Net Income
-$25,196K
Net Profit Margin
-31.45%
EPS
-$0.1
Unit: Thousand (K) dollars
Revenue Breakdown
Product
Collaboration Revenue
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-03-31
2025-12-31
2025-09-30
2025-06-30
Total revenues
80,104
151,557*
87,309
-
Cost of goods sold
34,573
19,984*
41,289
-
Research and development
8,988
7,820*
14,131
-
Selling, general and administrative
43,124
38,521*
41,848
-
Total operating expenses
86,685
66,324*
97,268
-
Loss from operations
-6,581
85,233
-9,959
7,095
Interest expense
19,798
22,636
22,051
20,486
Loss on extinguishment of debt and exchange transaction
-
-1,381
0
0
Other income, net
1,183
1,075
677
666
Loss before income taxes
-
62,291*
-
-
Provision for taxes on income
-
460*
-
-
Net gain
-25,196
61,831
-31,333
-12,725
Unrealized gain on investments
-
0
-
-
Comprehensive gain
-25,196
61,831
-31,333
-12,725
Basic EPS
-0.1
0.261
-0.16
-0.06
Diluted EPS
-0.1
0.261
-0.16
-0.06
Basic Average Shares
251,353,086
237,049,997
200,736,136
197,546,239
Diluted Average Shares
251,353,086
237,049,997
200,736,136
197,546,239
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Comprehensive gain
-$25,196K
(37.72%↑ Y/Y)
Net gain
-$25,196K
(37.72%↑ Y/Y)
Other income, net
$1,183K
(10.35%↑ Y/Y)
Product
$43,391K
Collaboration Revenue
$36,713K
Interest expense
$19,798K
(1.89%↑ Y/Y)
Loss from operations
-$6,581K
(70.22%↑ Y/Y)
Total revenues
$80,104K
(23.25%↑ Y/Y)
Total operating
expenses
$86,685K
(-0.47%↓ Y/Y)
Selling, general and
administrative
$43,124K
(0.30%↑ Y/Y)
Cost of goods sold
$34,573K
(9.62%↑ Y/Y)
Research and development
$8,988K
(-28.42%↓ Y/Y)
Buy us a coffee
Esperion Therapeutics, Inc. (ESPR)
Esperion Therapeutics, Inc. (ESPR)